{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:44:13Z","timestamp":1740109453213,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00408-022-00543-0","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T15:09:57Z","timestamp":1654614597000},"page":"315-323","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 3 Weeks of Orally Administered Gefapixant in Healthy Younger and Older Adults"],"prefix":"10.1007","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3591-7041","authenticated-orcid":false,"given":"Jesse","family":"Nussbaum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azher","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Butera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aubrey","family":"Stoch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"543_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.chest.2017.05.038","volume":"152","author":"Y \u00c7olak","year":"2017","unstructured":"\u00c7olak Y, Nordestgaard BG, Laursen LC et al (2017) Risk factors for chronic cough among 14,669 individuals from the general population. Chest 152:563\u2013573","journal-title":"Chest"},{"key":"543_CR2","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.chest.2017.10.016","volume":"153","author":"RS Irwin","year":"2018","unstructured":"Irwin RS, French CL, Chang AB et al (2018) Classification of cough as a symptom in adults and management algorithms: CHEST guideline and expert panel report. Chest 153:196\u2013209","journal-title":"Chest"},{"issue":"suppl 3","key":"543_CR3","first-page":"PA3327","volume":"54","author":"L McGarvey","year":"2019","unstructured":"McGarvey L, Morice A, Way N et al (2019) Prevalence of chronic cough, patient characteristics and health outcomes among UK adults. Eur Respir J 54(suppl 3):PA3327","journal-title":"Eur Respir J"},{"key":"543_CR4","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1016\/j.jaip.2021.07.022","volume":"9","author":"EO Meltzer","year":"2021","unstructured":"Meltzer EO, Zeiger RS, Dicpinigaitis P et al (2021) Prevalence and burden of chronic cough in the United States. J Allergy Clin Immunol Pract 9:4037-4044.e2","journal-title":"J Allergy Clin Immunol Pract"},{"key":"543_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00408-015-9701-2","volume":"193","author":"SAF Chamberlain","year":"2015","unstructured":"Chamberlain SAF, Garrod R, Douiri A et al (2015) The impact of chronic cough: a cross-sectional European survey. Lung 193:401\u2013408","journal-title":"Lung"},{"key":"543_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0025-6196(11)60967-1","volume":"82","author":"TJ Kuzniar","year":"2007","unstructured":"Kuzniar TJ, Morgenthaler TI, Afessa B et al (2007) Chronic cough from the patient\u2019s perspective. Mayo Clin Proc 82:56\u201360","journal-title":"Mayo Clin Proc"},{"key":"543_CR7","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.jaip.2019.04.012","volume":"7","author":"L McGarvey","year":"2019","unstructured":"McGarvey L, Gibson PG (2019) What is chronic cough? Terminology. J Allergy Clin Immunol Pract 7:1711\u20131714","journal-title":"J Allergy Clin Immunol Pract"},{"key":"543_CR8","doi-asserted-by":"publisher","first-page":"1901136","DOI":"10.1183\/13993003.01136-2019","volume":"55","author":"AH Morice","year":"2020","unstructured":"Morice AH, Millqvist E, Bieksiene K et al (2020) ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J 55:1901136","journal-title":"Eur Respir J"},{"key":"543_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nm1617","volume":"13","author":"M Idzko","year":"2007","unstructured":"Idzko M, Hammad H, van Nimwegen M et al (2007) Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med 13:913\u2013919","journal-title":"Nat Med"},{"key":"543_CR10","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.4049\/jimmunol.1003020","volume":"186","author":"H Kouzaki","year":"2011","unstructured":"Kouzaki H, Iijima K, Kobayashi T et al (2011) The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol 186:4375\u20134387","journal-title":"J Immunol"},{"key":"543_CR11","doi-asserted-by":"publisher","first-page":"L858","DOI":"10.1152\/ajplung.90360.2008","volume":"295","author":"K Kwong","year":"2008","unstructured":"Kwong K, Kollarik M, Nassenstein C et al (2008) P2X2 receptors differentiate placodal vs. neural crest C-fiber phenotypes innervating guinea pig lungs and esophagus. Am J Physiol Lung Cell Mol Physiol 295:L858\u2013L865","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"543_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00408-020-00377-8","volume":"198","author":"PV Dicpinigaitis","year":"2020","unstructured":"Dicpinigaitis PV, McGarvey LP, Canning BJ (2020) P2X3-receptor antagonists as potential antitussives: summary of current clinical trials in chronic cough. Lung 198:609\u2013616","journal-title":"Lung"},{"key":"543_CR13","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0140-6736(21)02348-5","volume":"399","author":"LP McGarvey","year":"2022","unstructured":"McGarvey LP, Birring SS, Morice AH et al (2022) Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, placebo-controlled phase 3 trials. Lancet 399:909\u2013923","journal-title":"Lancet"},{"key":"543_CR14","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/S0140-6736(14)61255-1","volume":"385","author":"R Abdulqawi","year":"2015","unstructured":"Abdulqawi R, Dockry R, Holt K et al (2015) P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 385:1198\u20131205","journal-title":"Lancet"},{"key":"543_CR15","doi-asserted-by":"publisher","first-page":"1901615","DOI":"10.1183\/13993003.01615-2019","volume":"55","author":"JA Smith","year":"2020","unstructured":"Smith JA, Kitt MM, Butera P et al (2020) Gefapixant in two randomised dose-escalation studies in chronic cough. Eur Respir J 55:1901615","journal-title":"Eur Respir J"},{"key":"543_CR16","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S2213-2600(19)30471-0","volume":"8","author":"JA Smith","year":"2020","unstructured":"Smith JA, Kitt MM, Morice AH et al (2020) Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet Respir Med 8:775\u2013785","journal-title":"Lancet Respir Med"},{"key":"543_CR17","unstructured":"MSD KK, KYORIN Holdings Inc (2022) MSD K.K. receives manufacturing and marketing approval of LYFNUA\u00ae Tablets, world's first selective P2X3 receptor antagonist for the treatment of chronic cough. https:\/\/www.kyorin-pharm.co.jp\/en\/news\/2022\/001603.shtml. Accessed 22 April 2022"},{"key":"543_CR18","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.jaip.2020.11.018","volume":"9","author":"RS Zeiger","year":"2021","unstructured":"Zeiger RS, Schatz M, Hong B et al (2021) Patient-reported burden of chronic cough in a managed care organization. J Allergy Clin Immunol Pract 9:1624-1637.e10","journal-title":"J Allergy Clin Immunol Pract"},{"key":"543_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40520-019-01464-4","volume":"32","author":"G Campi","year":"2020","unstructured":"Campi G, Noale M, Fabbrizzi A et al (2020) The demographic and clinical characteristics of an Italian population of adult outpatients with chronic cough. Aging Clin Exp Res 32:741\u2013746","journal-title":"Aging Clin Exp Res"},{"key":"543_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00408-021-00437-7","volume":"199","author":"AH Morice","year":"2021","unstructured":"Morice AH, Birring SS, Smith JA et al (2021) Characterization of patients with refractory or unexplained chronic cough participating in a phase 2 clinical trial of the P2X3-receptor antagonist gefapixant. Lung 199:121\u2013129","journal-title":"Lung"},{"key":"543_CR21","doi-asserted-by":"publisher","first-page":"00284","DOI":"10.1183\/23120541.00284-2020","volume":"6","author":"DR Muccino","year":"2020","unstructured":"Muccino DR, Morice AH, Birring SS et al (2020) Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough. ERJ Open Res 6:00284\u201302020","journal-title":"ERJ Open Res"},{"key":"543_CR22","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s12882-018-1126-8","volume":"19","author":"A Fenton","year":"2018","unstructured":"Fenton A, Montgomery E, Nightingale P et al (2018) Glomerular filtration rate: new age- and gender- specific reference ranges and thresholds for living kidney donation. BMC Nephrol 19:336","journal-title":"BMC Nephrol"},{"key":"543_CR23","doi-asserted-by":"publisher","first-page":"e00924","DOI":"10.1002\/prp2.924","volume":"10","author":"JC Nussbaum","year":"2022","unstructured":"Nussbaum JC, Hussain A, Ma B et al (2022) Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans. Pharmacol Res Perspect 10:e00924","journal-title":"Pharmacol Res Perspect"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-022-00543-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-022-00543-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-022-00543-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T14:12:04Z","timestamp":1655475124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-022-00543-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["543"],"URL":"https:\/\/doi.org\/10.1007\/s00408-022-00543-0","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"type":"print","value":"0341-2040"},{"type":"electronic","value":"1432-1750"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"28 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JN, AH, AS, and MI are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ USA, who may own stock and\/or hold stock options in the Company. AF, PB, and MK were employees of Afferent Pharmaceuticals at the time of the study (now acquired by Merck & Co., Inc., Rahway, NJ, USA) and may own stock and\/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA. SS was a consultant for Afferent Pharmaceuticals at the time of the study (now acquired by Merck and Co., Inc., Rahway, NJ, USA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in compliance with International Conference on Harmonisation Technical Requirements for Registration of Pharmaceuticals for Human Use E6, Good Clinical Practices: Consolidated Guidelines and any additional national or institutional review board-required procedures. The study protocol was approved by the Celerion Institutional Review Board and conducted at Celerion (Tempe, AZ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All participants provided written informed consent before enrollment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}